Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.
Investigated for use/treatment in hepatitis (viral, B).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.